Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Stopped Primary analysis was completed in 2018 and continued minimal data collection from the one participant active in the study was not expected to add meaningful knowledge to the understanding of lapatinib

Conditions

• Neoplasms, Breast

Interventions

• DRUG: Lapatinib
• BIOLOGICAL: Trastuzumab
• DRUG: Aromatase Inhibitors (AIs)

Sponsor

Novartis Pharmaceuticals